Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metformin-treated hESC-derived pancreatic organoids

ABSTRACT: Metformin-treated hESC-derived pancreatic organoids

PROVIDER: PRJNA549928 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9332050.fastq.gz	Fastqsanger.gz
	SRR9332060.fastq.gz	Fastqsanger.gz
	SRR9332051.fastq.gz	Fastqsanger.gz
	SRR9332061.fastq.gz	Fastqsanger.gz
	SRR9332052.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Metformin-treated hESC-derived pancreatic organoids

Project description:The goal of this study is to investigate transcriptome profiles (RNA-seq) of human embryonic stem cell (hESC)-derived pancreatic organoids with or without metformin treatment at various concentrations.

2021-10-03 | GSE133087 | GEO

Control or KZFP KD hESC-derived organoids RNA-seqs

Project description:Control or KD hESC were differentiated into organoids as decribed in Methods. RNA was extracted from individual organoids at day 20 after commencing the STEMdiff™ Cerebral Organoid Kit protocol. Day 0 was designated as the day of transfer of hESC to a 96-well plate for differentiation into embryoid bodies .

2020-02-18 | GSE145406 | GEO

The NAMPT inhibitor FK866 increases metformin sensitivity in pancreatic cancer cells

Project description:Pancreatic cancer (pancreatic ductal adenocarcinoma: PDAC) is one of the most aggressive neoplastic diseases. Metformin use was associated with reduced pancreatic cancer incidence or better survival in diabetics. Metformin has been shown to inhibit PDAC cells survival and growth in vitro and in vivo. However, clinical trials using metformin failed to decrease pancreatic cancer progression in patients, raising important questions about molecular mechanisms that protect tumor cells from the antineoplastic activities of metformin. We confirm that metformin acts through inhibition of mitochondrial complex I, decreasing the NAD+/NADH ratio and that NAD+/NADH homeostasis determines metformin sensitivity in several cancer cell lines. Metabolites that can restore the NAD+/NADH ratio turned PDAC cells resistant to metformin. In addition, metformin treatment of PDAC cell lines induced a compensatory NAMPT expression increasing the pool of cellular NAD+. The NAMPT inhibitor FK866 sensitized PDAC cells to the antiproliferative effects of metformin in vitro and decreased cellular NAD+ pool. Intriguingly, FK866 combined with metformin increased survival in mice bearing KP4 cells xenografts but not in mice with PANC1 xenografts. Transcriptome analysis revealed that the drug combination reactivated genes in the p53 pathway and oxidative stress providing new insights about the mechanisms leading to cancer cell death.

2023-06-01 | GSE210562 | GEO

DNA methylation in hESC derived brain organoids and iPSC derived neurons, astrocytes and neural progenitors

Project description:We studied the impact of ZIKA virus infection on DNA methylation in whole organoids, organoid derived astrocytes, neurons neural progeniotors and hESC or iPSC derived astrocytes, neurons, neural progenotor cells

2018-01-12 | GSE109104 | GEO

Control or KZFP KD hESC-derived organoids RNA-seqs

Project description:Control or KZFP KD hESC-derived organoids RNA-seqs

| PRJNA607091 | ENA

Modelling Plasticity and Dysplasia of Pancreatic Ductal Organoids Derived from Human Pluripotent Stem Cells

Project description:Full protein measurements from in vitro differentiation of the human embryonic stem cell line HUES8 into pancreatic progenitors (PP) and pancreatic duct-like organoids (PDLOs). Protein intensities were quantified by mass spectrometry analysis from PPs at day 13 and from PDLOs at day 59. Please see related publication “Modelling Plasticity and Dysplasia of Pancreatic Ductal Organoids Derived from Human Pluripotent Stem Cells” for experimental details.

2021-03-19 | PXD018785 | Pride

Transcriptome profiling of hESC-derived endoderm progenitors by RNA-seq

Project description:Transcriptome profiling of hESC-derived endoderm progenitors by RNA-seq. RNA-seq analysis during the stepwise progression of hESC toward the pancreatic progenitors, at five defined stages of differentiation and expansion: hESC, ADE, VFG.p3, VFG.p6. PE.

2022-11-15 | GSE185670 | GEO

A chemoproteomic map of compound candidate to arrest cell growth in pancreatic cancer patient-derived organoids

Project description:We here present a proteomic study of drug inhibiting the cell growth of pancreatic cancer patient-derived organoids

2024-05-27 | PXD031663 | Pride

Expression data from patient-derived pancreatic cancer organoids with gene engineering

Project description:Lineage plasticity often emerges in human cancer along with clinical progression and exposure to chemotherapy. Although lineage transition is evident in an aggressive subtype of human pancreatic cancer characterized by the loss of the ductal identity and manifestation of squamous cell-like features, the drivers of these processes have remained elusive. We here harmonized organoid technology, molecular profiling and gene engineering and found that the H3K27me3-mediated erasure of the ductal identity and lineage specifiers, and hijacking of the TP63-driven squamous-cell program provide environmental fitness. Induction and fixation of the squamous-cell identity was dependent on Wnt-deficient environment, whereas KDM6A loss or a hypoxic niche licensed tumor cells for squamous reprogramming. EZH2 inhibition counterbalanced the epigenetic bias and curbed the growth of pancreatic cancer organoids with squamous features. Our results demonstrate how adversarial microenvironment dictates the molecular and histological evolution of human pancreatic cancer, and provide insights into the principles and significance of lineage conversion in human cancer. We used microarray gene expression analysis to study the effect of delta-Np63 overexpression and TP63 knockout in patient-derived pancreatic cancer organoids or genetically engineered organoids.

2024-06-30 | GSE263236 | GEO

Inhibition of PC reverse metformin resistance pancreatic cancer

Project description:Inhibition of PC reverse metformin resistance pancreatic cancer

| PRJNA863102 | ENA